• Cheng Luo, Dongjuan He, HongBin Yang, Chunyan Zhu, Jiajun Zhu, and Zhaohui Hu.
• Department of Endocrinology, The Quzhou Affiliated of Wenzhou Medical University, Quzhou People's Hospital, Zhejiang, P.R. China.
• Afr Health Sci. 2022 Sep 1; 22 (3): 267274267-274.

IntroductionThe efficacy of liraglutide on renal function in type 2 diabetes remains controversial. We conduct a systematic review and meta-analysis to explore the influence of liraglutide versus placebo on renal function in type 2 diabetes.MethodsWe search PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through March 2020 for randomized controlled trials (RCTs) assessing the effect of liraglutide versus placebo on renal function in type 2 diabetes. This meta-analysis is performed using the random-effect model.ResultsSeven RCTs are included in the meta-analysis. Overall, compared with control group in type 2 diabetes, liraglutide treatment shows no obvious effect on GFR (SMD=0.02; 95% CI=-0.43 to 0.47; P=0.94), RBF (SMD=-0.28; 95% CI=-0.80 to 0.24; P=0.29) or death (RR=1.93; 95% CI=0.71 to 5.21; P=0.20), but is associated with significantly decreased ACR (SMD=-0.82; 95% CI=-1.39 to -0.26; P=0.004) and systolic blood pressure (MD=-9.60; 95% CI=-17.46 to -1.73; P=0.02), as well as increased heart rate (MD=5.39; 95% CI=3.26 to 7.52; P<0.00001).ConclusionsLiraglutide treatment may provide some benefits for protecting renal function in type 2 diabetes.© 2022 Luo C et al.

11 keywords...

hide…